Research and Development

Researchers at Lancaster University funded by the European Union are hoping to develop a new treatment for Alzheimer’s disease. Nanoparticles …

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

Pfizer has signed a deal with the University of California to help expand its drug discovery and development programme. The …

Takeda and Amylin have decided to halt further studies of its combination treatment for obesity, due to ‘evolving dynamics’ within …

Pfizer has pulled out of a $195 million deal with UK firm Biotica, as it continues to downsize its global …

Wainwright Associates is an independent company offering consultancy services to the pharmaceutical, medical device and healthcare industry in Product Development, …

Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …

Actelion’s prospective multiple sclerosis pill ponesimod has cheered the company by meeting its primary endpoint in a phase IIb trial. …

Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …

GlaxoSmithKline chief executive Andrew Witty has promised to expand operations in the UK in both manufacturing and R&D, saying that …

GlaxoSmithKline has posted a slide in revenue for the second quarter, but is buoyed by strong underlying growth. Sales were …

PPD plays down sell-off rumours, Icon sees a steep profit decline, plus updates from Beaufort, PharmaNet, ClinStar and Biofocus/IMD. PPD …

Bristol-Myers Squibb is to plug gaps in its pipeline by buying private biotech company Amira Pharmaceuticals for $325 million in …

Sanofi has appointed Anne Whitaker president of its US pharmaceutical operations. She joins the company from GlaxoSmithKline, where she served …

Lilly has presented a review of data from semagacestat, the Alzheimer’s drug it dropped last year after disappointing results. Phase …